Scarica l'app Stockscreener
4.76
5.03%
-0.21
Precedente Chiudi:
$4.97
Aprire:
$4.91
Volume 24 ore:
40,420
Relative Volume:
0.60
Capitalizzazione di mercato:
$15.27M
Reddito:
-
Utile/perdita netta:
$-45.52M
Rapporto P/E:
-0.4894
EPS:
-9.7265
Flusso di cassa netto:
$-31.51M
1 W Prestazione:
-17.34%
1M Prestazione:
-41.58%
6M Prestazione:
-28.92%
1 anno Prestazione:
+1,095%
Intervallo 1D:
$4.7027
$5.01
Intervallo di 1 settimana:
$4.7027
$5.82
Portata 52W:
$0.257
$20.00
Passage Bio Inc Stock (PASG) Company Profile
Nome
Passage Bio Inc
Settore
Industria
Telefono
(267) 866-0312
Indirizzo
ONE COMMERCE SQUARE, PHILADELPHIA, PA
Compare PASG vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PASG
Passage Bio Inc
|
4.76 | 15.94M | 0 | -45.52M | -31.51M | -9.7265 |
VRTX
Vertex Pharmaceuticals Inc
|
423.69 | 107.83B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
709.60 | 73.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
801.00 | 48.72B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
293.74 | 39.51B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
296.26 | 32.66B | 5.36B | 287.73M | 924.18M | 2.5229 |
Passage Bio Inc Stock (PASG) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-21 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2026-04-21 | Downgrade | TD Cowen | Buy → Hold |
| 2026-04-21 | Downgrade | Wedbush | Outperform → Neutral |
| 2026-03-31 | Iniziato | Oppenheimer | Outperform |
| 2026-02-10 | Ripresa | Chardan Capital Markets | Buy |
| 2024-11-29 | Ripresa | Wedbush | Outperform |
| 2024-09-03 | Iniziato | Rodman & Renshaw | Buy |
| 2022-03-08 | Downgrade | JP Morgan | Overweight → Neutral |
| 2022-01-19 | Downgrade | Goldman | Buy → Neutral |
| 2021-07-01 | Iniziato | Raymond James | Outperform |
| 2021-06-15 | Iniziato | BTIG Research | Buy |
| 2021-03-04 | Aggiornamento | Goldman | Neutral → Buy |
| 2021-02-04 | Iniziato | Guggenheim | Buy |
| 2021-01-25 | Iniziato | Wedbush | Outperform |
| 2021-01-04 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-12-11 | Iniziato | Citigroup | Neutral |
| 2020-08-14 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-06-25 | Downgrade | Goldman | Buy → Neutral |
| 2020-03-25 | Iniziato | Chardan Capital Markets | Buy |
| 2020-03-24 | Iniziato | Cowen | Outperform |
| 2020-03-24 | Iniziato | Goldman | Buy |
| 2020-03-24 | Iniziato | JP Morgan | Overweight |
Mostra tutto
Passage Bio Inc Borsa (PASG) Ultime notizie
Passage Bio Announces Major Workforce Reduction and Restructuring - TipRanks
Passage Bio (NASDAQ: PASG) slashes workforce by 75% in 2026 restructuring - Stock Titan
Passage Bio Reports Trial Data, Reviews Strategic Options - MyChesCo
Chardan Capital Maintains Passage Bio (PASG) Buy Recommendation - MSN
Canaccord Genuity Remains a Buy on Passage Bio (PASG) - The Globe and Mail
PASG Maintains Rating by Oppenheimer -- Price Target Lowered to $15 - GuruFocus
PASG Downgraded by Chardan Capital -- Price Target Lowered to $7 - GuruFocus
Passage Bio (PASG) Downgraded by Wedbush Analyst - GuruFocus
PASG Downgraded by TD Cowen -- Rating Changed to Hold - GuruFocus
Passage Bio Faces Tougher FDA Road After Trial Shift, Wedbush Says - marketscreener.com
PASG Downgraded by Wedbush -- Price Target Lowered to $8.00 - GuruFocus
Passage Bio Seen as Undervalued Despite FDA Setback, Oppenheimer Says - marketscreener.com
Passage Bio downgraded to Neutral from Buy at Chardan - TipRanks
This Mohawk Industries Analyst Is No Longer Bullish; Here Are Top 2 Downgrades For Tuesday - Benzinga
Passage Bio stock rating cut to Hold by TD Cowen on FDA trial news - Investing.com South Africa
Oppenheimer Adjusts Price Target on Passage Bio to $15 From $30, Maintains Outperform Rating - marketscreener.com
Wedbush Downgrades Passage Bio to Neutral From Outperform, Cuts Price Target to $8 From $32 - marketscreener.com
Oppenheimer cuts Passage Bio stock price target on regulatory setback - Investing.com
Oppenheimer cuts Passage Bio stock price target on regulatory setback By Investing.com - Investing.com Australia
Passage Bio Announces PBFT02 Data and Strategic Review - The Globe and Mail
Chardan Downgrades Passage Bio to Neutral From Buy, Cuts Price Target to $7 From $21 - marketscreener.com
Chardan downgrades Passage Bio stock rating on strategic review By Investing.com - Investing.com South Africa
Chardan downgrades Passage Bio stock rating on strategic review - Investing.com
Passage Bio to Present at H.C. Wainwright Global Investment Conference - MSN
Wedbush Maintains Passage Bio(PASG.US) With Buy Rating, Maintains Target Price $32 - Moomoo
New Developments for Passage Bio (PASG) in Frontotemporal Dement - GuruFocus
Is Passage Bio (PASG) stock safe today (Underperforming) 2026-04-20Viral Momentum Stocks - Xã Thanh Hà
Lucid downgrades Passage Bio stock rating on funding concerns By Investing.com - Investing.com South Africa
Lucid downgrades Passage Bio stock rating on funding concerns - Investing.com
Passage Bio Starts Strategic Review After FDA Doesn't Support Single-Arm Trial - Moomoo
Passage Bio Reports Positive Interim Data for PBFT02 in FTD-GRN, Initiates Strategic Review After FDA Guidance 1 - Minichart
Passage Bio reports biomarker improvements in FTD trial - Investing.com
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Passage Bio reports biomarker improvements in FTD trial By Investing.com - Investing.com Canada
Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates - The Manila Times
Gene therapy company Passage Bio, Inc. recently disclosed two major decisions: the official appointment of Wedbush Pacgrow as its financial advisor, and the commencement of a comprehensive evaluation of strategic alternatives. - Bitget
Strategic review at Passage Bio (NASDAQ: PASG) after FDA trial guidance - Stock Titan
Leading Companies Fueling Innovation and Growth in the GM1 Gangliosidosis Market - openPR.com
Short Squeeze: What is the earnings history of Passage Bio IncTrade Entry Report & Consistent Profit Focused Trading Strategies - baoquankhu1.vn
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
PMN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Trends in Growth, Segment Analysis, and Competitive Strategies Influencing the Adeno-Associated Viral Vectors Market - openPR.com
PASG PE Ratio & Valuation, Is PASG Overvalued - Intellectia AI
Passage Bio Inc Azioni (PASG) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.83%
2.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):